Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by retiredcopon May 05, 2021 6:23am
170 Views
Post# 33130283

RE:Explain This?

RE:Explain This?Might be a situation where the developer and owner of the test does not want  the information released to the  media quite yet ..soPMN does not have anything accurate they can release...

..the other thing is the third party that is apparently going to use this serology test....has listed the price she will charge for the test ...but the test is coming soon, not available yet and

The anticipated website for the test we think is the one we jv 'd , is restricted with a password after 1 day of public access...you have to wonder why that happened...

. I PERSONALLY don't think it is totally ready yet for  commercial use and for what ever reason the developer and owner of the test is taking this particular approach. Why is he marketing the product behind the scenes, but not acknowledging publically that it exists or is available. That troubles me but then it makes sense.... he has no obligation to anyone if he is a private company...

So maybe we should try and figure out why this is going the way it is...lets put our investigative abilities to work to find some kind of scientific publication on what this test can do...you would think it's got to be reported somewhere by the developer...because right now we are relying on info put out by a third party and they can slant the info to suit their needs

<< Previous
Bullboard Posts
Next >>